Evonik Rebuffs BASF's Opening Bid, but the Real Battle Is Just Beginning

Evonik turned down BASF's unsolicited EUR 22.15-per-share approach, valuing its equity near EUR 10.3 billion, as talks continue with the outcome left open.

Evonik has drawn a line in the sand. The Essen-based specialty chemicals group turned down an unsolicited approach from BASF, dismissing the Ludwigshafen giant's roughly EUR 22.15-per-share offer as too thin to justify opening its books or entering formal talks. The rejection, confirmed Monday and first reported by Reuters and the Financial Times, values Evonik's equity at approximately EUR 10.3 billion — a premium of nearly 29% to the share price before takeover speculation first surfaced.

BASF has acknowledged making informal contact on Friday but has stayed silent on the terms and the trajectory of those early soundings. For now, the two sides remain far apart on price, and that gap sits at the heart of everything that follows.

A Market Pricing in a Second Act

Investors clearly aren't treating the rebuff as the end of the story. Evonik shares climbed 2.0% in the prior session to close at EUR 19.88, just shy of their 52-week high of EUR 20.00. By Monday the stock was changing hands at EUR 19.79, up 1.8% on the day, inching back toward the level BASF had put on the table.

The standoff has handed the market a fresh set of variables. Evonik's management has made plain that a sale below fair value is not up for discussion, yet BASF has confirmed formal exploratory talks are underway — with the outcome explicitly left open. That combination has set off a phase of tactical reassessment among traders.

Broader forces are also at work. Europe's chemicals industry faces mounting consolidation pressure as high costs and structural overhauls weigh on balance sheets. A combination of the two groups would create a heavyweight with combined annual revenue of roughly EUR 74 billion.

The RAG-Stiftung Holds the Veto

No path to a deal runs around the RAG-Stiftung. The foundation controls just under 44% of Evonik's shares, and North Rhine-Westphalia's state premier, Hendrik Wüst, sits on its board of trustees. Without the anchor shareholder's explicit blessing, neither a hostile nor a friendly takeover is mathematically or politically feasible.

Labor has also raised its voice. Michael Vassiliadis, head of the chemicals union IGBCE, is pressing for concrete prospects and binding investment commitments covering the sites and workforces of both companies. Size alone, he argued, does not guarantee job security — a pointed warning given that both groups are already running their own cost-cutting programs. The union fears the roughly 31,000 Evonik employees worldwide could be stretched too far.

What Analysts See on Both Sides of the Trade

The DZ Bank maintains a "Buy" rating on Evonik with a EUR 22 price target, though its analysts caution that a definitive collapse of the talks could trigger painful share-price setbacks. Key transaction questions remain unresolved: investors are skeptical about how quickly synergies could be extracted, and they view BASF's ability to finance such a deal with doubt in a demanding market environment.

On the analytical front, the debate now centers on price. Deutsche Bank Research analyst Virginie Boucher-Ferte said after news of the talks emerged that the genie is out of the bottle. Should BASF need to raise its bid in earnest, a EUR 25-per-share mark comes into focus. The question is how far BASF can stretch financially without overextending its own balance sheet.

Bernstein analyst James Hooper noted that the pure numbers of such a combination look attractive, even if operational execution is complex. Baader Europe sees clear strategic synergies: complementary positions in isocyanates such as MDI and TDI, in catalysts and surfactants, and through combining BASF's vitamins division with Evonik's methionine business. If that logic prevails, an improved offer could pull Evonik's stock gradually toward EUR 25, quickly eroding existing valuation discounts. A signal from the RAG-Stiftung that it would engage above a certain price threshold would add further momentum, with investors betting on a deal backed by cash or stock.

The Downside If Talks Fall Apart

Against that upside stands a tangible risk of reversal. Should BASF deem the demands uneconomic and walk away entirely, the takeover premium would drain from the share price quickly. Because Evonik rebuffed the first approach so bluntly, an abrupt end to the soundings is a live possibility at any moment.

Antitrust hurdles add another layer of uncertainty. Baader Europe has flagged potential competition and antitrust risks, particularly in the segment for personal-care ingredients. If a merger forced the divestment of profitable business units under regulatory pressure, the economic appeal of the transaction would diminish.

Strip away the takeover fantasy, and the sector's fundamental problems return to center stage. Evonik would have to push its restructuring forward under its own steam. In that scenario, the stock could slide back to where it traded before the talks became public, as short-term arbitrage investors rush to unwind their positions.

The Weeks Ahead

So long as exploratory talks continue and BASF prepares a sweetened offer, Evonik's share price should find a floor beneath it from takeover speculation. If that process tips the other way — with BASF officially declaring the negotiations failed — the recent gains could be wiped out in short order. With a market capitalization of EUR 9.10 billion, the group remains dependent on a reliable foundation.

The next concrete catalyst is an official statement from the RAG-Stiftung or a fresh offer out of Ludwigshafen. Market participants are watching closely to see whether BASF takes the step toward a formal takeover bid or lets the talks fade without any convergence.